Mercer Global Advisors Inc. ADV Sells 39,782 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Mercer Global Advisors Inc. ADV cut its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 19.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 170,056 shares of the company’s stock after selling 39,782 shares during the period. Mercer Global Advisors Inc. ADV’s holdings in Takeda Pharmaceutical were worth $2,201,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of TAK. Rise Advisors LLC bought a new position in shares of Takeda Pharmaceutical in the first quarter worth $26,000. Principal Securities Inc. purchased a new position in Takeda Pharmaceutical during the 4th quarter valued at about $28,000. GAMMA Investing LLC grew its holdings in Takeda Pharmaceutical by 50.9% during the 1st quarter. GAMMA Investing LLC now owns 2,864 shares of the company’s stock valued at $40,000 after buying an additional 966 shares in the last quarter. Headlands Technologies LLC bought a new stake in shares of Takeda Pharmaceutical during the second quarter valued at about $59,000. Finally, Blue Trust Inc. lifted its holdings in shares of Takeda Pharmaceutical by 74.0% in the second quarter. Blue Trust Inc. now owns 5,480 shares of the company’s stock worth $76,000 after buying an additional 2,330 shares in the last quarter. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Price Performance

TAK stock opened at $14.91 on Tuesday. The firm has a 50 day moving average of $14.35 and a 200-day moving average of $13.75. The company has a current ratio of 1.26, a quick ratio of 0.74 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $47.19 billion, a P/E ratio of 27.11, a price-to-earnings-growth ratio of 0.27 and a beta of 0.54. Takeda Pharmaceutical Company Limited has a 12 month low of $12.57 and a 12 month high of $16.06.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings results on Wednesday, July 31st. The company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.19. Takeda Pharmaceutical had a net margin of 6.02% and a return on equity of 10.11%. The firm had revenue of $7.75 billion during the quarter. As a group, sell-side analysts predict that Takeda Pharmaceutical Company Limited will post 1.63 earnings per share for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.